Ferozsons Laboratories Limited (PSX:FEROZ)

Market Cap	15.83B -16.4%
Revenue (ttm)	22.68B +24.9%
Net Income	941.68M +25.0%
EPS	21.66 +25.0%
Shares Out	43.47M
PE Ratio	16.81
Forward PE	n/a
Dividend	4.00 (1.08%)
Ex-Dividend Date	Oct 16, 2025

Volume	20,564
Open	364.15
Previous Close	364.11
Day's Range	346.50 - 371.97
52-Week Range	293.01 - 475.00
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 23, 2026

About Ferozsons Laboratories

Ferozsons Laboratories Limited, together with its subsidiaries, engages in the importing, manufacturing, and sale of pharmaceutical products and medical devices in Pakistan, Afghanistan, Sri Lanka, the Philippines, Kenya, Myanmar, Kyrgyzstan, Mongolia, Cambodia, and internationally. The company offers products in various therapeutic areas of anti-fungal, anti-viral, antibiotics, cardiometabolic, cough, dermatology, diabetes, gastrointestinal and liver, oncology, orthopedic, and urology and nephrology areas. It also provides medical devices in t...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1954
• Employees: 1,556
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: FEROZ

Financial Performance

In fiscal year 2025, Ferozsons Laboratories's revenue was 18.86 billion, an increase of 18.94% compared to the previous year's 15.85 billion. Earnings were 776.54 million, an increase of 13.67%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 20, 2026

Data Sources Report a data error